Novel bacterial topoisomerase inhibitors: unique targeting activities of amide enzyme-binding motifs for tricyclic analogs
Antimicrobial Agents and Chemotherapy · 2023
DOI: 10.1128/aac.00482-23 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2023. Verfasst von Chelsea A Mann und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University , Columbus, Ohio, USA. Hauptthemen laut MEDLINE: Topoisomerase Inhibitors, DNA Gyrase. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, HHS | National Institutes of Health, Dr. Ralph and Marian Falk Medical Research Trust.
Abstract (Originalsprache)
Antimicrobial resistance has made a sizeable impact on public health and continues to threaten the effectiveness of antibacterial therapies. Novel bacterial topoisomerase inhibitors (NBTIs) are a promising class of antibacterial agents with a unique binding mode and distinct pharmacology that enables them to evade existing resistance mechanisms. The clinical development of NBTIs has been plagued by several issues, including cardiovascular safety. Herein, we report a sub-series of tricyclic NBTIs bearing an amide linkage that displays promising antibacterial activity, potent dual-target inhibition of DNA gyrase and topoisomerase IV (TopoIV), as well as improved cardiovascular safety and metabolic profiles. These amide NBTIs induced both single- and double-strand breaks in pBR322 DNA mediated by Staphylococcus aureus DNA gyrase, in contrast to prototypical NBTIs that cause only single-strand breaks. Unexpectedly, amides 1a and 1b targeted human topoisomerase IIα (TOP2α) causing both single- and double-strand breaks in pBR322 DNA, and induced DNA strand breaks in intact human leukemia K562 cells. In addition, anticancer drug-resistant K/VP.5 cells containing decreased levels of TOP2α were cross-resistant to amides 1a and 1b . Together, these results demonstrate broad spectrum antibacterial properties of selected tricyclic NBTIs, desirable safety profiles, an unusual ability to induce DNA double-stranded breaks, and activity against human TOP2α. Future work will be directed toward optimization and development of tricyclic NBTIs with potent and selective activity against bacteria. Finally, the current results may provide an additional avenue for development of selective anticancer agents.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University , Columbus, Ohio, USA.
- Division of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University , Columbus, Ohio, USA.
- Department of Microbial Infection and Immunity, College of Medicine, The Ohio State University , Columbus, Ohio, USA.
ORCID-Profile: Jack C Yalowich, Mark J Mitton-Fry
Förderung
- NIAID NIH HHS
- HHS | National Institutes of Health
- Dr. Ralph and Marian Falk Medical Research Trust
- Jack L. Beal Fellowship
- Chih-Ming and Jane Chen Graduate Fellowship Fund
Zitieren
APA
Mann, C. A., Carvajal Moreno, J. J., Lu, Y., Dellos-Nolan, S., Wozniak, D. J., Yalowich, J. C., & Mitton-Fry, M. J. (2023). Novel bacterial topoisomerase inhibitors: unique targeting activities of amide enzyme-binding motifs for tricyclic analogs. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00482-23
Vancouver
Mann CA, Carvajal Moreno JJ, Lu Y, Dellos-Nolan S, Wozniak DJ, Yalowich JC, et al. Novel bacterial topoisomerase inhibitors: unique targeting activities of amide enzyme-binding motifs for tricyclic analogs. Antimicrobial Agents and Chemotherapy. 2023. doi:10.1128/aac.00482-23
BibTeX
@article{Mann2023,
author = {Mann, Chelsea A and Carvajal Moreno, Jessika J and Lu, Yanran and Dellos-Nolan, Sheri and Wozniak, Daniel J and Yalowich, Jack C and Mitton-Fry, Mark J},
title = {Novel bacterial topoisomerase inhibitors: unique targeting activities of amide enzyme-binding motifs for tricyclic analogs},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2023},
doi = {10.1128/aac.00482-23}
}
EUVIMED